By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OvaGene Oncology has completed a licensing and collaboration agreement with the Moffitt Cancer Center to develop and commercialize proprietary microRNA assays to predict drug response for currently used cancer drugs, the Irvine, Calif.-based molecular diagnostics firm announced on Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.